BIRC5 and precursor B-cell acute lymphoblastic leukemia: Immunotherapeutic strategies, such as those targeting survivin, would complement the existing use of immunotherapy for patients with adult B-ALL who often receive DLIs to boost their allogeneic transplants and enhance survival.